These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
22. A 52-week, multinational, open-label, parallel-group, noninferiority, treat-to-target trial comparing insulin detemir with insulin glargine in a basal-bolus regimen with mealtime insulin aspart in patients with type 2 diabetes. Hollander P, Cooper J, Bregnhøj J, Pedersen CB. Clin Ther; 2008 Nov; 30(11):1976-87. PubMed ID: 19108786 [Abstract] [Full Text] [Related]
23. Switching from NPH insulin to once-daily insulin detemir in basal-bolus-treated patients with diabetes mellitus: data from the European cohort of the PREDICTIVE study. Sreenan S, Virkamäki A, Zhang K, Hansen JB, PREDICTIVE study group. Int J Clin Pract; 2008 Dec; 62(12):1971-80. PubMed ID: 19166444 [Abstract] [Full Text] [Related]
25. Comparison of lunch and bedtime NPH insulin plus mealtime insulin Lispro therapy with premeal regular insulin plus bedtime NPH insulin therapy in type 2 diabetes. Sargin H, Sargin M, Altuntaş Y, Sengül AM, Orbay E, Seber S, Uçak S, Yayla A. Diabetes Res Clin Pract; 2003 Nov; 62(2):79-86. PubMed ID: 14581144 [Abstract] [Full Text] [Related]
26. [Optimal timing of insulin detemir injection in patients with type 1 diabetes and poor metabolic control]. Segovia Portolés R, Ferrer-García JC, Merino-Torres JF, Penalba MT, Albalat Galera R, Piñón-Selles F. Endocrinol Nutr; 2010 Apr; 57(4):140-6. PubMed ID: 20347404 [Abstract] [Full Text] [Related]
27. A randomized multicentre trial of insulin glargine compared with NPH insulin in people with type 1 diabetes. Home PD, Rosskamp R, Forjanic-Klapproth J, Dressler A, European Insulin Glargine Study Group. Diabetes Metab Res Rev; 2005 Apr; 21(6):545-53. PubMed ID: 16021649 [Abstract] [Full Text] [Related]
29. Comparison of insulin degludec with insulin detemir in type 1 diabetes: a 1-year treat-to-target trial. Davies M, Sasaki T, Gross JL, Bantwal G, Ono Y, Nishida T, Tojjar D, Seino H. Diabetes Obes Metab; 2016 Jan; 18(1):96-9. PubMed ID: 26435472 [Abstract] [Full Text] [Related]
31. Reduced weight gain with insulin detemir compared to NPH insulin is not explained by a reduction in hypoglycemia. Davies MJ, Derezinski T, Pedersen CB, Clauson P. Diabetes Technol Ther; 2008 Aug; 10(4):273-7. PubMed ID: 18715200 [Abstract] [Full Text] [Related]
32. Basal insulin glargine (HOE 901) versus NPH insulin in patients with type 1 diabetes on multiple daily insulin regimens. U.S. Insulin Glargine (HOE 901) Type 1 Diabetes Investigator Group. Rosenstock J, Park G, Zimmerman J, U.S. Insulin Glargine (HOE 901) Type 1 Diabetes Investigator Group. Diabetes Care; 2000 Aug; 23(8):1137-42. PubMed ID: 10937511 [Abstract] [Full Text] [Related]
33. Similar glucose control with basal-bolus regimen of insulin detemir plus insulin aspart and thrice-daily biphasic insulin aspart 30 in insulin-naive patients with type 2 diabetes: Results of a 50-week randomized clinical trial of stepwise insulin intensification. Malek R, Ajili F, Assaad-Khalil SH, Shinde A, Chen JW, Van den Berg E. Diabetes Metab; 2015 Jun; 41(3):223-30. PubMed ID: 25483023 [Abstract] [Full Text] [Related]
34. Lower within-subject variability of fasting blood glucose and reduced weight gain with insulin detemir compared to NPH insulin in patients with type 2 diabetes. Haak T, Tiengo A, Draeger E, Suntum M, Waldhäusl W. Diabetes Obes Metab; 2005 Jan; 7(1):56-64. PubMed ID: 15642076 [Abstract] [Full Text] [Related]
35. Effects of multiple daily injection therapy with Humalog mixtures versus separately injected insulin lispro and NPH insulin in adults with type I diabetes mellitus. Roach P, Bai S, Charbonnel B, Consoli A, Taboga C, Tiengo A, Bolli G, High Mix Study Group. Clin Ther; 2004 Apr; 26(4):502-10. PubMed ID: 15189747 [Abstract] [Full Text] [Related]
36. A randomized clinical trial comparing breakfast, dinner, or bedtime administration of insulin glargine in patients with type 1 diabetes. Hamann A, Matthaei S, Rosak C, Silvestre L, HOE901/4007 Study Group. Diabetes Care; 2003 Jun; 26(6):1738-44. PubMed ID: 12766103 [Abstract] [Full Text] [Related]
37. Efficacy and safety of insulin detemir once daily in combination with sitagliptin and metformin: the TRANSITION randomized controlled trial. Hollander P, Raslova K, Skjøth TV, Råstam J, Liutkus JF. Diabetes Obes Metab; 2011 Mar; 13(3):268-75. PubMed ID: 21205123 [Abstract] [Full Text] [Related]
38. Lower fasting blood glucose, glucose variability and nocturnal hypoglycaemia with glargine vs NPH basal insulin in subjects with Type 1 diabetes. Bolli GB, Songini M, Trovati M, Del Prato S, Ghirlanda G, Cordera R, Trevisan R, Riccardi G, Noacco C. Nutr Metab Cardiovasc Dis; 2009 Oct; 19(8):571-9. PubMed ID: 18676131 [Abstract] [Full Text] [Related]
39. Glargine is superior to neutral protamine Hagedorn for improving glycated haemoglobin and fasting blood glucose levels during intensive insulin therapy. Fulcher GR, Gilbert RE, Yue DK. Intern Med J; 2005 Sep; 35(9):536-42. PubMed ID: 16105155 [Abstract] [Full Text] [Related]
40. Maternal efficacy and safety outcomes in a randomized, controlled trial comparing insulin detemir with NPH insulin in 310 pregnant women with type 1 diabetes. Mathiesen ER, Hod M, Ivanisevic M, Duran Garcia S, Brøndsted L, Jovanovic L, Damm P, McCance DR, Detemir in Pregnancy Study Group. Diabetes Care; 2012 Oct; 35(10):2012-7. PubMed ID: 22851598 [Abstract] [Full Text] [Related] Page: [Previous] [Next] [New Search]